Medarex/BMS Working To Shift Ipilimumab Trial Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
Overall survival is more valid than freedom from progression in Phase III melanoma trial, firm says.
You may also be interested in...
ASCO Abstracts Hold Some Surprises Including Data On AZ’s Vandetanib, Bristol’s Ipilimumab
Despite the lack of innovative drugs highlighted in ASCO's media briefing on its upcoming annual meeting, there is a range of oncology development updates that will be presented - including some surprises
ASCO Abstracts Hold Some Surprises Including Data On AZ’s Vandetanib, Bristol’s Ipilimumab
Despite the lack of innovative drugs highlighted in ASCO's media briefing on its upcoming annual meeting, there is a range of oncology development updates that will be presented - including some surprises
True To Its Cancer Focus, Medarex Outlicenses C. Diff Therapy To Merck
Medarex and partner Massachusetts Biologic Laboratories will split equally $60 million upfront and potential milestones worth $165 million.